M. Gribbin

发表

Power calculation for overall hypothesis testing with high‐dimensional commensurate outcomes

Jacqueline L Johnson, Keith E. Muller, Yueh-Yun Chi, 2014, Statistics in medicine.

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

T. Ciuleanu, M. Rodríguez-Torres, I. Bondarenko, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Fractional anisotropy distributions in 2- to 6-year-old children with autism.

G. Gerig, H. Hazlett, S. Gouttard, 2012, Journal of intellectual disability research : JIDR.

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

R. Ferris, N. Rizvi, B. Keam, 2020, Clinical Cancer Research.

Phase I study of MEDI0639 in patients with advanced solid tumors.

David C. Smith, A. Naing, A. Dowlati, 2015 .

Confidence regions for repeated measures ANOVA power curves based on estimated covariance

Yueh-Yun Chi, Keith E Muller, Matthew J Gribbin, 2013, BMC Medical Research Methodology.

Global hypothesis testing for high‐dimensional repeated measures outcomes

Yueh-Yun Chi, Keith E Muller, J. Gregory, 2012, Statistics in medicine.

Better power methods for the univariate approach to repeated measures

M. Gribbin, Matthew Joseph Gribbin, 2007 .

Analytic, Computational, and Approximate Forms for Ratios of Noncentral and Central Gaussian Quadratic Forms

Keith E Muller, Douglas J. Taylor, Matthew J Gribbin, 2006, Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America.

Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

J. von Pawel, D. Camidge, D. Spigel, 2014, Clinical lung cancer.

Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.

L. Chow, O. Hamid, J. Gray, 2015 .

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.

R. Ferris, N. Rizvi, V. Chiou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies

O. Hamid, J. Gray, L. Chow, 2016 .

Brief report: How well do clinic-based blood pressure measurements agree with the mercury standard?

Martha B. Adams, C. Voils, H. Bosworth, 2005, Journal of General Internal Medicine.

Abstract 5045: Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignancies

L. Roskos, R. Narwal, M. Gribbin, 2017 .

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

L. Recht, M. Birrer, N. Rizvi, 2018, Clinical Cancer Research.

POWERLIB: SAS/IML Software for Computing Power in Multivariate Linear Models.

Sean L Simpson, Keith E Muller, Jacqueline L Johnson, 2009, Journal of statistical software.

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

T. Ciuleanu, G. Aktan, I. Bondarenko, 2014 .